SSRI CHINA news

Hitoshi, Kio and Ryusuke, along with many of our SSRI staffs in Japan attended the APRC (The Asia Pacific Research Committee) and JMRA (Japan Market Research Association) joint annual conference in Tokyo. We had a booth promoting our viewing facility in Japan (West5), and Ryusuke did a presentation with Mr. Greg Chu of InTask, Inc.

Jane, Kio, Hitoshi, and Levis attended the China Pharma Decision Science Summit and CphMRA Annual meeting 2016 in Beijing. We had a nice booth, and Jane did a presentation about our China COPD report. Good job Jane! ...but why is my collar sticking out... .
The details of our China COPD report can be found here; click here (PDF file)

SSRI CHINA and its headquarter Social Survey Research Information Co., Ltd. (SSRI) have recently completed a syndicated market research study on China’s COPD Market. This report provides extensive information from secondary research and primary research based on 200 COPD treaters, covering a range of topics from current diagnosis and treatment, current prescription and satisfaction, and future outlook on the market.

• Increasing number of patients, with physicians and the government authorities citing air pollution as a cause
• The most commonly used product for COPD is ICS/LABA with 73% usage
• Within the 17 pipeline products, awareness of Boehringer Ingelheim's olodaterol (Striverdi) is the highest with 52%
• GSK has the highest sales rep visitation rate with 51%

For more details; click here (PDF file)

Jane, Kio and Hitoshi attended the EphMRA Annual Conference 2016 in Frankfurt, Germany with Ito from our Japan international market research operations team. Good turnout this year with many clients.

This photo; courtesy of GFK (Thank you!)

Jane and Hitoshi attended the PBIRG Annual general Meeting in Florida with staffs from our headquarters. According to their feedback, there were not many clients this year...